Ask ten athletes where to source vasoactive intestinal peptide and most will start typing into a search bar before anyone raises the question that actually matters first: should someone under anti-doping testing be using it at all. That ordering problem is the source of most of the confusion around VIP. People treat it as a shopping question when it is really a permissions question wearing a shopping question’s clothes. This piece tries to untangle the two, in the order they actually need to be answered.
VIP is a compounded medication that is not approved by the FDA. Athletes should consult both a licensed clinician and their sport’s anti-doping authority before considering it.
Where the confusion starts
Here is the honest state of things. Vasoactive intestinal peptide does not appear by name on the World Anti-Doping Agency’s Prohibited List. Plenty of sellers stop right there, as if a name search settles it. It doesn’t, and the reason is worth sitting with.
WADA’s list has a catch-all category, Section S0, for non-approved substances. It prohibits, at all times, any pharmacological substance not currently approved by a governmental regulatory health authority for human therapeutic use, the kind of thing still in preclinical or clinical development, or discontinued, or simply never cleared. VIP is compounded, not FDA-approved as a therapy, which means it plausibly sits inside that catch-all even without ever being individually named. The only body that can tell a tested athlete definitively where they stand is their own anti-doping organization, in writing. Not a vendor’s FAQ page. Not this article either.
There is a second layer of confusion sitting underneath the first, and it has nothing to do with whether VIP itself is allowed. Because VIP is sold heavily through the gray “research chemical” market, a real portion of what ships under that label carries a risk of being misidentified, contaminated, or simply not what the label says. Anti-doping systems generally run on strict liability: an athlete is responsible for whatever turns up in their body, however it got there. A vial that turns out to contain something extra, or something different, isn’t a mitigating story. It’s a positive test. For most people that’s a quality complaint. For a tested athlete it’s a career event.
Put those two things together and the sensible default comes into focus on its own: treat VIP as high-risk and off-limits until a governing body says otherwise, and understand that even resolving the substance question doesn’t resolve the sourcing-quality question underneath it.
Where the clarification comes from: what the science actually shows
Some of the confusion also comes from the evidence itself getting oversold, so it’s worth being precise about what’s actually been shown.
VIP’s anti-inflammatory and immune-regulating biology is well documented in laboratory and preclinical work, including its role in suppressing inflammatory mediators like TNF-alpha and supporting regulatory T cells (PMID 22139413). In small early human trials for specific conditions, it has looked promising: inhaled VIP lowered pulmonary artery pressure in a small pulmonary hypertension study (PMID 12727925), and nebulized VIP was safe and reduced inflammatory signaling in the lungs in a phase II sarcoidosis trial (PMID 20442436).
Those are real findings, but they’re narrow, and they sit against a much bigger negative result. TESICO, a large randomized, placebo-controlled trial of synthetic VIP (aviptadil) in COVID-related respiratory failure, enrolled more than 460 patients and found no benefit at all. It was stopped early for futility (PMID 37348524). For the uses athletes are actually chasing, recovery, general inflammation, circadian effects, there is no comparable body of controlled human evidence showing a benefit. VIP is a biologically interesting molecule with unproven benefits in athletes specifically. That single fact should lower, not raise, anyone’s appetite for sourcing risk.
The sensible path: routes that behave like healthcare
None of the routes below turn VIP into an FDA-approved, anti-doping-cleared therapy. What separates them from the rest of the market is that they strip out the risks that are actually avoidable, wrong identity, non-sterile manufacture, zero oversight, leaving only the risks that come baked into VIP itself.
FormBlends is the clearest example of this done properly, and for someone operating in a context where use is permitted and clinician-supervised, it’s the route that holds up best under scrutiny. Independent licensed clinicians make the clinical call, the product is dispensed by licensed US 503A compounding pharmacies for an identified patient rather than shipped as an anonymous vial, and the company says outright, in its own materials, that its compounded medications are not FDA-approved and haven’t been evaluated by the FDA for safety, effectiveness, or quality.
For an athlete specifically, the value here is identity and quality control, not a doping clearance. A product built by a licensed compounding pharmacy against a clinician’s order is far less likely to be the misidentified or contaminated material that drives gray-market positives. That doesn’t erase strict-liability exposure, and it doesn’t answer the S0 question, both of those still belong to the athlete’s anti-doping authority, but it removes the one layer of risk that was always avoidable. Cost runs from roughly $120 a month at the low end, a figure that reflects actual clinical oversight and licensed dispensing rather than a bare product markup. FormBlends also offers a tracker app for logging doses and personal response over time. Worth using for self-knowledge, not worth mistaking for clinical proof of anything.
HealthRX sits right behind it, running the same essential model: physician-supervised, dispensed through a licensed US compounding pharmacy, upfront about the not-FDA-approved status rather than burying it. It ranks second on depth of substance-specific support, not on legitimacy. Both belong in the same category, the one where someone is actually accountable for what’s in the vial.
A third defensible option isn’t a brand at all, it’s a structure: a physician who, where permissible, evaluates the athlete directly, documents a real clinical decision, and sources through a licensed pharmacy. Same safeguards as the two above, with the advantage that this clinician can speak to the anti-doping question directly, including whether a therapeutic use exemption might even apply.
And then there’s a fourth path that deserves to be named plainly rather than tucked away: not sourcing it at all. Given unproven benefits, plausible S0 exposure, and strict liability turning any contamination into the athlete’s own problem, the math for a tested athlete with a career to protect often comes out negative before it even starts. That’s not a rhetorical flourish. On the evidence, it’s frequently the right call.
The routes that just move the risk onto the buyer
A handful of sellers sit at the other end of this, and what they share is a legal framing built to enable a sale while disclaiming responsibility for it.
Biotech Peptides sells under a “research use only, not for human consumption” label with some self-published testing, the label itself being what allows a sale without a prescription, clinician, or pharmacy in the loop. Amino Asylum runs cheap and high-volume with thin documentation, close to the worst combination available for someone facing strict liability. Core Peptides posts COAs on some products, a modest step up, but still self-reported, still no clinician, still no pharmacy accountable to a patient. Swiss Chems runs the same broad “research only” catalog with the same structural gap.
None of these are choices worth weighing seriously for a tested athlete. They’re listed so the pattern is recognizable, not so it can be shopped.
A shortcut worth knowing: every one of these checks is really the same question
The source material behind this piece lists seven separate checks for telling a defensible source from an indefensible one. It’s worth noticing something about that list: almost every item is asking one question dressed up seven different ways, which is if something goes wrong here, is there a specific accountable person on the other end of it?
- Anti-doping status addressed honestly, not glossed over or spun as automatically fine.
- A real licensed clinician, not a checkout page pretending to be one.
- A licensed pharmacy dispensing to a named patient, the single strongest defense against the misidentification behind contamination positives.
- The regulatory truth stated outright, that this is compounded and not FDA-approved.
- Identity and sterility controlled inside an actual quality system, not a seller’s self-issued certificate.
- Accountability after the sale, a clinician or pharmacist who owns the outcome.
- Strict liability, understood by the athlete personally, that whatever is in the vial becomes their responsibility under anti-doping rules no matter what the label promised.
A source clearing the first six describes the supervised end of this market. Item seven is different from the rest, because no vendor can clear it for the athlete. That one has to be settled directly with the athlete’s own anti-doping authority, and it’s the one that deserves the most attention rather than the least.
The sensible path, stated once more
For athletes, VIP sits at an intersection of two open questions: a compound whose recovery and performance benefits in humans remain unproven, and an anti-doping status that, while not a named prohibition, plausibly falls under the non-approved-substances catch-all and needs resolving by the athlete’s own governing body. Where sourcing is on the table at all, the defensible routes are the supervised, pharmacy-dispensed ones, FormBlends first, HealthRX close behind, because they take the identity and quality risk off the buyer’s plate. For a lot of tested athletes, though, the most defensible route is the one the evidence quietly points toward anyway: not sourcing it, and certainly not from the gray market, until a clinician and an anti-doping authority have actually weighed in.
VIP is a compounded medication that is not approved by the FDA. Athletes should consult a licensed clinician and their anti-doping authority before considering it.
What readers ask most
Is VIP banned by WADA? Not by name. But that absence isn’t a clearance. WADA’s Section S0 prohibits, at all times, any pharmacological substance not currently approved by a governmental regulatory health authority for human therapeutic use, and a compounded peptide without FDA approval plausibly fits inside that catch-all. Only the athlete’s own anti-doping organization can give a definitive answer, in writing. Until then, the sensible default is to treat VIP as high-risk and off-limits.
Can I fail a drug test from VIP even if the substance itself turns out to be allowed? Yes. Because VIP moves heavily through the gray “research chemical” market, vials in that channel carry a real risk of being misidentified, contaminated, or mislabeled. Anti-doping systems generally run on strict liability, meaning an athlete is responsible for whatever is in their body regardless of how it got there. A vial containing something other than what the label claims isn’t a defense. It’s a positive test.
Is a compounding pharmacy actually safer for athletes than a research-chemical seller? Safer on the avoidable risks, not the unavoidable ones. Product made by a licensed US 503A compounding pharmacy under a clinician’s order is far less likely to be the misidentified or contaminated material that drives gray-market positives. That removes one avoidable layer of risk. It doesn’t erase strict-liability exposure and it doesn’t answer the S0 question, both of which stay with the athlete’s anti-doping authority.
What does the supervised, pharmacy-dispensed route actually cost? Roughly $120 a month at the low end of the range. That figure reflects real clinical oversight and licensed-pharmacy dispensing, the exact pieces missing from the cheaper research-chemical sellers.
Is there solid evidence VIP improves recovery or performance in athletes? No. The anti-inflammatory biology is well characterized in preclinical work, and small early human trials in pulmonary hypertension and sarcoidosis were encouraging, but a large randomized trial of synthetic VIP (aviptadil) in COVID-related respiratory failure found no benefit and was stopped for futility. For the recovery and inflammation uses athletes are actually interested in, there’s no comparable controlled human evidence showing benefit.
What’s the single safest choice for a tested athlete? Often, simply not sourcing it. With unproven benefits, plausible S0 exposure, and strict liability turning any contamination into the athlete’s own problem, the math frequently comes out negative for someone with a competitive career at stake. Any decision to move forward should wait on a clinician and the athlete’s anti-doping authority.
References
- Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013. PMID 22139413. https://pubmed.ncbi.nlm.nih.gov/22139413/ . Review of VIP’s anti-inflammatory and immune-regulatory biology.
- Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. Journal of Clinical Investigation. 2003. PMID 12727925. https://pubmed.ncbi.nlm.nih.gov/12727925/ . Small study; inhaled VIP lowered pulmonary artery pressure and improved cardiac output.
- Prasse A, Zissel G, Lützen N, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. American Journal of Respiratory and Critical Care Medicine. 2010. PMID 20442436. . Phase II trial; nebulized VIP was safe and reduced lung inflammatory signaling.
- Brown SM, Barkauskas CE, Grund B, et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. The Lancet Respiratory Medicine. 2023. PMID 37348524. . Large RCT (over 460 patients) of synthetic VIP (aviptadil); no benefit, stopped for futility.
On the regulatory status of compounded drugs, see the FDA’s overview of human drug compounding: . On the anti-doping framework referenced above, athletes should consult the current WADA Prohibited List and their national or sport anti-doping organization directly.
What is VIP peptide and what does it actually do in the body?
VIP, short for vasoactive intestinal peptide, is a 28-amino-acid signaling molecule the body already makes on its own. It acts on receptors across the lungs, gut, brain, and immune tissue, relaxing smooth muscle, helping regulate inflammation, and playing a role in circadian rhythms. Athletes have gotten curious about it mainly for possible effects on airway tone and systemic inflammation, though human data on giving it as a drug from outside the body is still pretty thin.
Where does WADA actually stand on VIP peptide?
VIP isn’t currently named on the WADA Prohibited List, but that’s not the same as being cleared. WADA’s catch-all provisions cover peptide hormones and related substances with similar structure or biological effect to listed compounds, which means VIP could still trigger a violation depending on how a case is interpreted. Anyone subject to anti-doping testing should get an actual ruling from their sport’s governing body rather than treating a name search of the list as the final word.
What are the realistic side effects of VIP peptide?
The effects reported most consistently in clinical and research settings are facial flushing, a temporary drop in blood pressure, and mild nausea, particularly with intravenous or higher-dose use. Inhaled forms have shown a gentler profile in small studies, but long-term safety data in healthy athletic populations doesn’t really exist yet. Anyone claiming it’s been fully safety-profiled for sport use is stretching what the evidence actually supports.
Where can athletes actually source VIP peptide without walking into legal or safety trouble?
The only route with real accountability attached is a licensed compounding pharmacy working under physician supervision, where the compound gets tested for purity and dosed with care. Some athletes have gone through services like FormBlends, which operates within that physician-supervised compounding model. Research-chemical sites and generic supplement sellers offer none of that structure, and purity testing on those products is inconsistent at best. The question of where to source it and the question of whether it’s safe to use turn out to be the same question.
